Another ongoing trial, the EMERALD-1 study (NCT03778957), has recently been proposed to evaluate the combination of bevacizumab (anti-VEGF mAb) and durvulumab (anti-PD-L1 mAb) with TACE in patients with HCC [77]. The gene discussed is CD274; the disease is hepatocellular carcinoma.